Biomediq is a leading research-based company specializing in the development and implementation of quantitative imaging biomarkers. Their cutting-edge solutions are designed for use in clinical trials and patient diagnosis, prognosis, screening, and monitoring. With a focus on improving trial design and providing valuable insights, Biomediq's software-based solutions offer automated analysis of scans to deliver precise and quantitative markers.

The company's comprehensive range of products and services includes knee MRI analysis, addressing cartilage quantity and quality, bone structure analysis related to osteoarthritis, mammograms for breast cancer risk assessment, brain MRI analysis for Alzheimer's disease, and hand MRI analysis for rheumatoid arthritis. These solutions are backed by machine learning technologies, leveraging vast databases of patient information to develop new markers. Each marker undergoes rigorous validation through clinical studies.

Biomediq collaborates with industry leaders like Nordic Bioscience, CCBR-Synarc, Novartis, and esteemed institutions including Erasmus Medical Center and Mayo Clinic. With a focus on major therapeutic areas such as osteoarthritis, rheumatoid arthritis, breast cancer, and Alzheimer's disease, Biomediq is committed to revolutionizing clinical research and providing transformative insights for improved patient care